Overview of premature and retarded ejaculation
Keywords:
Ejaculatory dysfunction, premature ejaculation, retarded ejaculation treatmentAbstract
Frequently met in clinical sexology as in general medicine, ejaculatory troubles had a multifactorial etiopathogeny and are subjects to controversies. Their therapies remain difficult despite different possible approaches.
Downloads
References
Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, D.C.: American Psychiatric Association, 1994.
Waldinger MD, Hengeveld MW, Zwinderman AH, Olivier B. An empirical operationalization study of DSM-IV diagnostic criteria for premature ejaculation. Int J Psychiatry Clin Pract 1998; 2: 287-93.
Screponi E, Carosa E, Di Stasi SM, Pepe M, Carruba G, Jannini EA. Prevalence of chronic prostatitis in men with premature ejaculation. Urology. 2001; 58: 198-202. 7
Carani C, Isidori AM, Granata A, et al. Multicenter study on the prevalence of sexual symptoms in male hypo- and hyperthyroid patients. J Clin Endocrinol Metab. 2005; 90: 6472-9.
Althof SE. Psychological treatment strategies for rapid ejaculation: rationale, practical aspects, and outcome. World J Urol. 2005; 23: 89-92.
St Lawrence JS, Madakasira S. Evaluation and treatment of premature ejaculation: a critical review. Int J Psychiatry Med. 1992; 22: 77-97.
Hartmann U, Schedlowski M, Krüger TH. Cognitive and partnerrelated factors in rapid ejaculation: differences between dysfunctional and functional men. World J Urol. 2005; 23: 93- 101.
Waldinger MD. Lifelong premature ejaculation: definition, serotonergic neurotransmission and drug treatment. World J Urol. 2005; 23:102-8.
Montague DK, Jarow J, Broderick GA, et al. AUA Erectile Dysfunction Guideline Update Panel. AUA guideline on the pharmacologic management of premature ejaculation. J Urol. 2004; 172: 290-4.
Waldinger MD, Berendsen HH, Blok BF, Olivier B, Holstege G. Premature ejaculation and serotonergic antidepressants-induced delayed ejaculation: the involvement of the serotonergic system. Behav Brain Res. 1998; 92: 111-8.
Nazareth I, Boynton P, King M. Problems with sexual function in people attending London general practitioners: cross sectional study. BMJ. 2003; 327: 423.
Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999; 281: 537-44.
Waldinger MD, Quinn P, Dilleen M, Mundayat R, Schweitzer DH, Boolell M. A multinational population survey of intravaginal ejaculation latency time. J Sex Med. 2005; 2: 492-7.
Waldinger MD, Zwinderman AH, Olivier B, Schweitzer DH. Proposal for a definition of lifelong premature ejaculation based on epidemiological stopwatch data. J Sex Med. 2005; 2: 498-507.
Waldinger MD, Zwinderman AH, Schweitzer DH, Olivier B. Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: a systematic review and meta-analysis. Int J Impot Res. 2004; 16: 369-81.
Waldinger MD, Zwinderman AH, Olivier B. On-demand treatment of premature ejaculation with clomipramine and paroxetine: a randomized, double-blind fixed-dose study with stopwatch assessment. Eur Urol. 2004; 46: 510-5.
Berkovitch M, Keresteci AG, Koren G. Efficacy of prilocainelidocaine cream in the treatment of premature ejaculation. J Urol. 1995; 154: 1360-1.
Busato W, Galindo CC. Topical anaesthetic use for treating premature ejaculation: a double-blind, randomized, placebocontrolled study. BJU Int. 2004; 93: 1018-21.
Chen J, Mabjeesh NJ, Matzkin H, Greenstein A. Efficacy of sildenafil as adjuvant therapy to selective serotonin reuptake inhibitor in alleviating premature ejaculation. Urology. 2003; 61: 197-200.
Salonia A, Maga T, Colombo R, et al. A prospective study comparing paroxetine alone versus paroxetine plus sildenafil in patients with premature ejaculation. J Urol. 2002; 168: 2486-9.
McMahon CG, Stuckey BG, Andersen M, et al. Efficacy of sildenafil citrate (Viagra) in men with premature ejaculation. J Sex Med. 2005; 2: 368-75.
Hellstrom W, Gittelman M, Althoff S, et al. Dapoxetine HCl for the treatment of premature ejaculation; a phase II, randomized, double-blind, placebo-controlled study. J Sex Med. 2004; 1: 59.
Waldinger MD. Lifelong premature ejaculation: from authoritybased to evidence-based medicine. BJU Int. 2004; 93: 201-7.
Waldinger MD. Relevance of an evidence-based ejaculation time cutoff point for neurobiological research of premature ejaculation. J Comp Neurol. 2005; 493: 46-50.
Olivier B, van Oorschot R, Waldinger MD. Serotonin, serotonergic receptors, selective serotonin reuptake inhibitors and sexual behaviour. Int Clin Psychopharmacol. 1998; 13 Suppl 6:S9-14.
Fuller RW. Uptake inhibitors increase extracellular serotonin concentration measured by brain microdialysis. Life Sci. 1994; 55: 163-7.
de Montigny C, Blier P, Caillé G, Kouassi E. Pre- and postsynaptic effects of zimelidine and norzimelidine on the serotoninergic system: single cell studies in the rat. Acta Psychiatr Scand Suppl. 1981; 290:79-90.
Waldinger MD, Schweitzer DH, Olivier B. On-demand SSRI treatment of premature ejaculation: pharmacodynamic limitations for relevant ejaculation delay and consequent solutions. J Sex Med. 2005; 2: 121-31.
Mos J, Mollet I, Tolboom JT, Waldinger MD, Olivier B. A comparison of the effects of different serotonin reuptake blockers on sexual behaviour of the male rat. Eur Neuropsychopharmacol. 1999; 9: 123-35.
Ahlenius S, Larsson K. Synergistic actions of the 5-HT1A receptor antagonist WAY-100635 and citalopram on male rat ejaculatory behavior. Eur J Pharmacol. 1999; 379: 1-6.
de Jong TR, Pattij T, Veening JG, et al. Citalopram combined with WAY 100635 inhibits ejaculation and ejaculation-related Fos immunoreactivity. Eur J Pharmacol. 2005; 509: 49-59.
Blier P, De Montigny C. Electrophysiological investigations on the effect of repeated zimelidine administration on serotonergic neurotransmission in the rat. J Neurosci. 1983; 3: 1270-8.
Chaput Y, Blier P, de Montigny C. In vivo electrophysiological evidence for the regulatory role of autoreceptors on serotonergic terminals. J Neurosci. 1986; 6: 2796-801.
Lanteri C, Salomon L, Torrens Y, Glowinski J, Tassin JP. Drugs of abuse specifically sensitize noradrenergic and serotonergic neurons via a non-dopaminergic mechanism. Neuropsychopharmacology. 2008; 33: 1724-34.
Cantor JM, Binik YM, Pfaus JG. Chronic fluoxetine inhibits sexual behavior in the male rat: reversal with oxytocin. Psychopharmacology (Berl). 1999; 144: 355-62.
Waldinger MD, Schweitzer DH. Retarded ejaculation in men: an overview of psychological and neurobiological insights. World J Urol. 2005; 23: 76-81.
Munjack DJ, Kanno PH. Retarded ejaculation: a review. Arch Sex Behav. 1979; 8: 139-50.
Baum MJ, Everitt BJ. Increased expression of c-fos in the medial preoptic area after mating in male rats: role of afferent inputs from the medial amygdala and midbrain central tegmental field. Neuroscience. 1992; 50: 627-46.
Coolen LM, Peters HJ, Veening JG. Fos immunoreactivity in the rat brain following consummatory elements of sexual behavior: a sex comparison. Brain Res. 1996 28; 738: 67-82.
Ahlenius S, Larsson K. Failure to antagonize the 8-hydroxy-2-din- propylamino-tetralin-induced facilitation of male rat sexual behavior by the administration of 5-HT receptor antagonists. Eur J Pharmacol. 1984; 99: 279-86.
Foreman MM, Hall JL, Love RL. Effects of fenfluramine and para-chloroamphetamine on sexual behavior of male rats. Psychopharmacology (Berl). 1992; 107: 327-30.
Nathan SG. The epidemiology of the DSM-III psychosexual dysfunctions. J Sex Marital Ther. 1986; 12: 267-81.
Haensel SM, Mos J, Olivier B, Slob AK. Sex behavior of male and female Wistar rats affected by the serotonin agonist 8-OHDPAT. Pharmacol Biochem Behav. 1991; 40: 221-8.
